# Berkshire Hathaway Inc: financial statements, quarterly

BRK-B · NYSE · CIK 1067983 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/brk-b.md) · [Financials](/companies/brk-b/financials.md) · [Filings](/companies/brk-b/filings.md) · [Insiders](/companies/brk-b/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/brk-b/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [65.2](/filings/0000950170-24-120241.md) | [64.6 d](/filings/0001193125-26-083899.md) | [61.3](/filings/0000950170-25-063112.md) | [63.5](/filings/0000950170-25-101578.md) | [62.0](/filings/0001193125-25-261548.md) | [62.9 d](/filings/0001193125-26-083899.md) | [59.4](/filings/0001193125-26-202243.md) | [61.4](/filings/0001193125-26-341032.md) | [63.7](/filings/0001193125-25-261548.md) | [62.7 d](/filings/0001193125-26-083899.md) | [63.1](/filings/0001193125-26-202243.md) | [70.1](/filings/0001193125-26-341032.md) |
| Operating income | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $bn | not reported | not reported | [1.3](/filings/0000950170-25-063112.md) | [1.2](/filings/0000950170-25-101578.md) | [1.2](/filings/0001193125-25-261548.md) | [1.4 d](/filings/0001193125-26-083899.md) | [1.3](/filings/0001193125-26-202243.md) | [1.3](/filings/0001193125-26-341032.md) | [1.3](/filings/0001193125-25-261548.md) | [1.3 d](/filings/0001193125-26-083899.md) | [1.3](/filings/0001193125-26-202243.md) | [1.3](/filings/0001193125-26-341032.md) |
| Income tax | $bn | [(4.4)](/filings/0000950170-24-120241.md) | [9.2 d](/filings/0001193125-26-083899.md) | [2.9](/filings/0000950170-25-063112.md) | [7.6](/filings/0000950170-25-101578.md) | [6.0](/filings/0001193125-25-261548.md) | [4.3 d](/filings/0001193125-26-083899.md) | [0.5](/filings/0001193125-26-202243.md) | [2.3](/filings/0001193125-26-341032.md) | [7.2](/filings/0001193125-25-261548.md) | [5.2 d](/filings/0001193125-26-083899.md) | [2.1](/filings/0001193125-26-202243.md) | [6.3](/filings/0001193125-26-341032.md) |
| Net income | $bn | [(12.8)](/filings/0000950170-24-120241.md) | [37.6 d](/filings/0001193125-26-083899.md) | [12.7](/filings/0000950170-25-063112.md) | [30.3](/filings/0000950170-25-101578.md) | [26.3](/filings/0001193125-25-261548.md) | [19.7 d](/filings/0001193125-26-083899.md) | [4.6](/filings/0001193125-26-202243.md) | [12.4](/filings/0001193125-26-341032.md) | [30.8](/filings/0001193125-25-261548.md) | [19.2 d](/filings/0001193125-26-083899.md) | [10.1](/filings/0001193125-26-202243.md) | [25.7](/filings/0001193125-26-341032.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [1,020](/filings/0000950170-23-058993.md) | [1,070](/filings/0000950170-25-025210.md) | [1,070](/filings/0000950170-24-053185.md) | [1,109](/filings/0000950170-24-090305.md) | [1,147](/filings/0000950170-24-120241.md) | [1,154](/filings/0001193125-26-083899.md) | [1,165](/filings/0000950170-25-063112.md) | [1,164](/filings/0000950170-25-101578.md) | [1,226](/filings/0001193125-25-261548.md) | [1,222](/filings/0001193125-26-341032.md) | [1,252](/filings/0001193125-26-202243.md) | [1,263](/filings/0001193125-26-341032.md) |
| Total liabilities | $bn | [485](/filings/0000950170-23-058993.md) | [499](/filings/0000950170-25-025210.md) | [492](/filings/0000950170-24-053185.md) | [501](/filings/0000950170-24-090305.md) | [515](/filings/0000950170-24-120241.md) | [502](/filings/0001193125-26-083899.md) | [508](/filings/0000950170-25-063112.md) | [494](/filings/0000950170-25-101578.md) | [526](/filings/0001193125-25-261548.md) | [502](/filings/0001193125-26-341032.md) | [523](/filings/0001193125-26-202243.md) | [513](/filings/0001193125-26-341032.md) |
| Shareholders' equity | $bn | [525](/filings/0000950170-23-058993.md) | [561](/filings/0000950170-25-025210.md) | [571](/filings/0000950170-24-053185.md) | [602](/filings/0000950170-24-090305.md) | [629](/filings/0000950170-24-120241.md) | [649](/filings/0001193125-26-083899.md) | [654](/filings/0000950170-25-063112.md) | [668](/filings/0000950170-25-101578.md) | [698](/filings/0001193125-25-261548.md) | [717](/filings/0001193125-26-341032.md) | [727](/filings/0001193125-26-202243.md) | [748](/filings/0001193125-26-341032.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $bn | [13.7 d](/filings/0000950170-24-120241.md) | [14.4 d](/filings/0001193125-26-083899.md) | [10.6](/filings/0000950170-25-063112.md) | [13.6 d](/filings/0000950170-25-101578.md) | [1.8 d](/filings/0001193125-25-261548.md) | [4.6 d](/filings/0001193125-26-083899.md) | [10.9](/filings/0001193125-26-202243.md) | [10.1 d](/filings/0001193125-26-341032.md) | [13.8 d](/filings/0001193125-25-261548.md) | [11.2 d](/filings/0001193125-26-083899.md) | [10.4](/filings/0001193125-26-202243.md) | [11.2 d](/filings/0001193125-26-341032.md) |
| Capital expenditure | $bn | [5.3 d](/filings/0000950170-24-120241.md) | [5.7 d](/filings/0001193125-26-083899.md) | [4.4](/filings/0000950170-25-063112.md) | [4.5 d](/filings/0000950170-25-101578.md) | [4.7 d](/filings/0001193125-25-261548.md) | [5.3 d](/filings/0001193125-26-083899.md) | [4.3](/filings/0001193125-26-202243.md) | [4.9 d](/filings/0001193125-26-341032.md) | [5.6 d](/filings/0001193125-25-261548.md) | [6.2 d](/filings/0001193125-26-083899.md) | [5.0](/filings/0001193125-26-202243.md) | [5.6 d](/filings/0001193125-26-341032.md) |
| Share repurchases | $bn | [1.1 d](/filings/0000950170-24-120241.md) | [2.2 d](/filings/0001193125-26-083899.md) | [2.6](/filings/0000950170-25-063112.md) | [0.4 d](/filings/0000950170-25-101578.md) | [0.0 d](/filings/0001193125-25-261548.md) | [0.0 d](/filings/0001193125-26-083899.md) | not reported | not reported | not reported | not reported | [0.2](/filings/0001193125-26-202243.md) | [4.2 d](/filings/0001193125-26-341032.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 941,481 at 2011-04-29, from the cover of the [10-Q filed 2011-05-06](/filings/0001157523-11-002891.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.